Document Detail


Low-molecular-weight heparin overdose: management by observation.
MedLine Citation:
PMID:  20923945     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: To describe 3 episodes of low-molecular-weight heparin (LMWH) overdose in 2 patients and discuss the clinical presentations, outcomes, and therapeutic options.
CASE SUMMARIES: The first patient, a 35-year-old female, presented after an intentional overdose of 72,000 units of dalteparin. The peak measured anti-Xa activity was 6.2 U/mL at 7.5 hours postinjection. No interventions were performed and there were no bleeding complications. The patient presented 20 days later following another overdose of 72,000 units. Anti-Xa activity was 4.5 U/mL 2 hours postinjection. No treatment was given and the patient was discharged with plans for follow-up the next day. There was no evidence of bleeding complications on follow-up. The second patient, a 29-year-old male, presented after an intentional overdose of 480 mg of enoxaparin. The anti-Xa activity was 1.9 U/mL measured 2 hours postinjection. The patient was observed without intervention. There were no bleeding complications.
DISCUSSION: To our knowledge, there is only one previous report of an LMWH overdose in the literature, an iatrogenic overdose in an infant treated with protamine. In our 3 presented episodes of LMWH overdose, no therapeutic interventions were performed and there were no bleeding complications. Review of the literature regarding the efficacy of protamine and recombinant factor VIIa for reversal of LMWH coagulopathy revealed that protamine is only partially effective and recombinant factor VIIa is effective in in vitro studies and case reports.
CONCLUSIONS: In cases of LMWH overdose, observation seems to be appropriate in the absence of clinically significant bleeding. Prolonged monitoring may be necessary for patients with renal failure. Use of protamine or recombinant factor VIIa is not supported by this case series in patients without significant bleeding. There is a lack of data regarding how to treat patients with significant bleeding.
Authors:
Andrew A Monte; Michael Bodmer; Tammi H Schaeffer
Related Documents :
19664015 - Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients bein...
11728145 - Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-spec...
7305525 - Massive hemoptysis: control by transcatheter bronchial artery embolization.
19120905 - Proton pump inhibitors and recurrent bleeding in peptic ulcer disease.
21811855 - The effect of knee position on blood loss and range of motion following total knee arth...
9260225 - Changes in the dentition secondary to palatal crib therapy in digit-suckers: a prelimin...
Publication Detail:
Type:  Journal Article     Date:  2010-10-05
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1836-9     Citation Subset:  IM    
Affiliation:
Rocky Mountain Poison and Drug Center, University of Colorado Denver, USA. Andrew.Monte@rmpdc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Education...A must in all levels of pharmacy practice.
Next Document:  Potential risk of medication discrepancies and reconciliation errors at admission and discharge from...